Avid Bioservices, Inc. (CDMO)
After hours:
- Motley Fool
Avid Bioservices, Inc. (CDMO) Q4 2022 Earnings Call Transcript
On today's call, we have Nick Green, president and CEO; Dan Hart, chief financial officer; and Matt Kwietniak, Avid's chief commercial officer. Today, we will be providing an overview of Avid Bioservices contract development and manufacturing business, including updates on corporate activities and financial results for the quarter and year ended April 30, 2022.
- GlobeNewswire
Avid Bioservices Reports Financial Results for Fourth Quarter and Full Fiscal Year Ended April 30, 2022 and Recent Developments
-- Recorded Fourth Quarter and Full Fiscal Year Revenue of $31 Million and $120 Million, Respectively -- -- Signed $44 Million in Net New Business Orders and Ended the Quarter with a Record High Backlog of $153 Million -- -- New Cell and Gene Therapy Analytical and Process Development Suites Now Operational and CGMP Manufacturing Suites Continue On Schedule; Myford South Facility Construction On Schedule -- -- Project Fiscal 2023 Revenue of $140 to $145 Million, Representing 17% - 21% Growth Ove
- GlobeNewswire
Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2022 After Market Close on June 29, 2022
TUSTIN, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the quarter and fiscal year ended April 30, 2022 on June 29, 2022 after market close and will host a conference call and webcast at 1:30 PM Pacific Time (4:30
